US life sciences M&A; seven megadeals over $5B in Q1 2026
Healthy returns: US life sciences M&A on track for a banner year | M&A Explorer
US life sciences M&A is showing strong vitals. Dealmaking is regaining momentum after a period of recalibration following the pandemic, and industry leaders are increasingly turning to transactions to maintain a competitive edge.
Several converging factors are accelerating this surge in activity. AI-fueled innovation continues to drive change and unlock new opportunities, while strong corporate balance sheets and a return of sponsor-led activity are providing the financial means to execute large-scale transactions. Likewise, a looming patent expiration cliff and the anticipated easing of interest rates are also reinforcing a strong case for M&A.
After three relatively subdued years, the US life sciences sector produced its fourth-highest annual deal value on record in 2025, totalingUS$322.1 billion. Notably, dealmaking accelerated as the year progressed, with aggregate deal value rising toUS$125 billionin the fourth quarter.
This momentum has carried over to 2026, withseven megadeals(transactions valued greater than US$5 billion) announced in the first quarter alone. Total deal value in the first quarter of 2026 reachedUS$108.6 billion, marking a 22 percent year-on-year increase and highlighting a positive market trajectory. At the time of writing (April 24), there had been a further 57 deals in the sector, valued at US$21.1 billion.
The year began with Boston Scientific’s acquisition of medtech company Penumbra. Valued at US$14.5 billion, the deal highlights the rising importance of cardiovascular products as an aging population and the increasing prevalence of heart conditions drive demand.
In a step away from its core business, US diagnostics company Danaher agreed to acquire global health tech company Masimo for US$9.9 billion as it looks to broaden its diagnostic segment. Based in California, Masimo is best known for creating devices that measure blood oxygen levels as well as other non-invasive monitors. Along with its rival, Medtronic, Masimo currently leads the market for blood oxygen monitoring products.
Another significant deal saw biopharma company Gilead Sciences acquire its cancer therapy partner Arcellx for the sum of US$7.8 billion. The companies are currently working to develop an experimental blood cancer therapy.
Sleep disorder therapy is another area attracting major investment, with US drugmaker Eli Lilly acquiring Centessa Pharmaceuticals in a US$7.8 billion deal. The purchase of the UK-based company, which is developing a new class of sleep disorder treatments, moves beyond Lilly’s traditional metabolic portfolio. The sleep disorder industry is a high-growth area, with between 50 million and 70 million Americans suffering from a sleep disorder, according to the US National Institutes of Health (NIH).
In a bid to strengthen its rare disease portfolio, US biotech company Biogen agreed to buy Apellis Pharmaceuticals, a company focused on developing therapies for rare diseases. The US$5.6 billion deal gives Biogen a foothold in the kidney disease market as it looks to expand beyond its multiple sclerosis franchise.
Drivers and expectations for 2026
Looking ahead, several factors are set to drive US life sciences M&A in both the short and long term. Sector uncertainty has eased considerably, as recent government agreements with industry leaders have provided clarity on pricing and tariff impact. This has left the industry with pent-up demand and the necessary financial firepower to pursue mega-mergers.
Looming patent expirations are another near-term incentive for dealmaking. Patent expiries across the global pharma industry threaten an estimated US$61 billion in sales annually through 2030, according to investment firm Bernstein’s estimates. As a result, companies will turn to M&A to replenish their pipelines and preserve top-line growth.
Dealmaker interest in weight-loss and GLP-1 drugs is particularly strong as rising consumer and business demand drive profit expectations. Neurology, central nervous system, oncology and cardio
metabolic categories are also attracting increasing attention as companies look to expand existing pipelines and pursue growth through strategic acquisitions.
Investment in AI technology is rising sharply across the life sciences sector, increasing appetite for strategic partnerships, joint ventures and M&A. According to arecent White & Case report, the US is a natural target market for AI investment in the life sciences sector, with North America accounting for 49.3 percent of the global AI-in-healthcare market. The US is particularly attractive from a regulatory standpoint, with the FDA taking measures to reduce ambiguity surrounding compliance and review standards.
Private equity activity in the US life sciences sector has also been a key M&A driver, with PE-backed deals rebounding in 2025 to reachUS$126 billion—the second-highest annual value on record, following 2021. Investors are expected to remain active in 2026, driven by aging portfolios and ample levels of dry powder. The first quarter of the year got off to a strong start, with activity totalingUS$33.9 billion. At the time of writing (April 24), this year’s total had risen to US$46 billion, with more than US$12 billion of deals in the first three weeks of April alone.
While the outlook for US life sciences M&A is positive, several challenges remain that could cause dealmaker confidence and deal momentum to falter.
At the sector level, shifts in US policy related to drug pricing could dampen future profitability. The industry is currently adapting to the “most-favored nation” (MFN) drug pricing executive order. Initiated in May 2025, this aims to benchmark certain brand-named drug prices against those in Organisation for Economic Co-operation and Development nations.
Yet there remains uncertainty about how the new pricing strategy will be operationalized, and companies that fail to comply risk regulatory scrutiny. The policy states that the FDA could potentially refuse or revoke drug approvals if manufacturers do not explore MFN-aligned strategies.
Cuts to NIH and other government funding are also adding to the pressure for earlier-stage companies to secure private capital financing or strategic partners.
Another challenge is that the US life sciences sector is navigating a volatile trading environment. Companies with supply chain exposure to certain countries, such as China and India, face steep tariffs on the import of certain goods. Industry leaders including Pfizer, Eli Lilly and Merck have struck agreements with the US government, securing relief on certain tariffs in exchange for commitments on domestic drug pricing and manufacturing.
More pressingly, ongoing tensions in the Middle East could potentially result in drug shortages and higher prices for generic prescriptions. The US is heavily reliant on these prescription shipments from India, a country that relies on crude oil and petrochemical inputs via the Strait of Hormuz in its own pharmaceutical manufacturing. As such, rerouting these shipments could place additional financial and logistical pressure on companies.
While challenges persist at both the macro and sectoral level, they are unlikely to stop industry heavyweights from pursuing deals in the near term.
Changing industry dynamics present a strong rationale for continued M&A. AI technology is no longer an optional add-on but a core driver of top-line growth as tech-enabled care becomes the norm. This is putting pressure on companies to enhance their portfolios through M&A.
If the dealmaking momentum from the first three months of 2026 continues—and there is every reason to believe that it will—the US life sciences sector could be on track for a record-breaking year. However, success will hinge on dealmakers learning to navigate policy and pricing shifts while remaining alert to geopolitical developments.
Receive M&A Explorer quarterly email updates when new data is available